NuCana (NCNA) Cash from Operations (2017 - 2025)
NuCana's (NCNA) quarterly Cash from Operations came in at 1529691.13 in Q4 2025, up 84.01% year-on-year from 831293.92 in Q4 2024, and down 188.7% quarter-over-quarter from 1724484.82 in Q3 2025.
NuCana (NCNA) Cash from Operations (2017 - 2025) Analysis & Trends
NuCana has disclosed Cash from Operations across 9 years of filings, most recently posting 1529691.13 for Q4 2025.
- Cash from Operations for Q4 2025 came in at 1529691.13, up 84.01% year-over-year; the trailing twelve-month figure through Dec 2025 was 15354391.18 (up 37.32% YoY), and the FY2025 annual result was 9845316.68, up 59.71% from the prior year.
- Cash from Operations came in at 1529691.13 for Q4 2025 at NuCana, down from 1724484.82 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1724484.82 in Q3 2025 to a low of 16425688.21 in Q4 2022.
- The 5-year median for Cash from Operations is 7392209.14 (2023), against an average of 7092460.88.
- Across the five-year window, Cash from Operations jumped 237.42% in 2022 and tumbled 9912.18% in 2024, its largest moves.
- NuCana's Cash from Operations stood at 13598731.01 in 2021, then retreated by 20.79% to 16425688.21 in 2022, then surged by 99.42% to 95568.7 in 2023, then sank by 9912.18% to 9568506.21 in 2024, then soared by 84.01% to 1529691.13 in 2025.
- The last three Cash from Operations figures came in at 1529691.13 (Q4 2025), 1724484.82 (Q3 2025), and 9568506.21 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | -1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.53 Mn |
| Dec 31, 2025 | -1.53 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Dec 31, 2023 | -95,568.70 |
| Dec 31, 2023 | -95,568.70 |
| Sep 30, 2023 | -12.89 Mn |
| Sep 30, 2023 | -12.89 Mn |
| Jun 30, 2023 | -7.32 Mn |
| Jun 30, 2023 | -7.32 Mn |
| Mar 31, 2023 | -12.56 Mn |
| Mar 31, 2023 | -12.56 Mn |